Загрузка...
Community Clinical Practice Patterns and Mortality in Patients with Oncotype DX Intermediate Score: Who benefits from Chemotherapy?
BACKGROUND: Oncotype DX recurrence score (RS) is used as a tool for making decision about chemotherapy in hormone receptor-positive, HER2-negative breast cancer. There is no benefit of chemotherapy in node negative, RS 11–25, age ≥50 patients but the benefit of chemotherapy in the node positive grou...
Сохранить в:
| Опубликовано в: : | Cancer |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6329644/ https://ncbi.nlm.nih.gov/pubmed/30387876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31818 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|